South Korea
· Delayed Price · Currency is KRW Pharmicell Statistics
Total Valuation
Pharmicell has a market cap or net worth of KRW 307.22 billion.
| Market Cap | 307.22B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmicell has 60.00 million shares outstanding.
| Shares Outstanding | 60.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.98% |
| Owned by Insiders (%) | 11.42% |
| Owned by Institutions (%) | 9.04% |
| Float | 52.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.33 |
| PB Ratio | 2.74 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.34 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.50 |
| Interest Coverage | -7.48 |
Financial Efficiency
Return on equity (ROE) is -29.25% and return on invested capital (ROIC) is -5.33%.
| Return on Equity (ROE) | -29.25% |
| Return on Assets (ROA) | -4.98% |
| Return on Capital (ROIC) | -5.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.21 |
| Inventory Turnover | 5.05 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.88% in the last 52 weeks. The beta is -1.22, so Pharmicell's price volatility has been lower than the market average.
| Beta (5Y) | -1.22 |
| 52-Week Price Change | -19.88% |
| 50-Day Moving Average | 5,652.90 |
| 200-Day Moving Average | 5,736.73 |
| Relative Strength Index (RSI) | 39.61 |
| Average Volume (20 Days) | 742,420 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmicell had revenue of KRW 23.94 billion and -26.78 billion in losses. Loss per share was -613.75.
| Revenue | 23.94B |
| Gross Profit | 5.45B |
| Operating Income | -9.29B |
| Pretax Income | -26.75B |
| Net Income | -26.78B |
| EBITDA | -6.18B |
| EBIT | -9.29B |
| Loss Per Share | -613.75 |
Balance Sheet
The company has 9.44 billion in cash and 11.74 billion in debt, giving a net cash position of -2.30 billion or -38.34 per share.
| Cash & Cash Equivalents | 9.44B |
| Total Debt | 11.74B |
| Net Cash | -2.30B |
| Net Cash Per Share | -38.34 |
| Equity (Book Value) | 84.27B |
| Book Value Per Share | 1,867.90 |
| Working Capital | 4.72B |
Cash Flow
In the last 12 months, operating cash flow was -7.55 billion and capital expenditures -272.69 million, giving a free cash flow of -7.82 billion.
| Operating Cash Flow | -7.55B |
| Capital Expenditures | -272.69M |
| Free Cash Flow | -7.82B |
| FCF Per Share | -130.32 |
Margins
Gross margin is 22.74%, with operating and profit margins of -38.80% and -111.85%.
| Gross Margin | 22.74% |
| Operating Margin | -38.80% |
| Pretax Margin | -111.71% |
| Profit Margin | -111.85% |
| EBITDA Margin | -25.83% |
| EBIT Margin | -38.80% |
| FCF Margin | -32.66% |
Dividends & Yields
Pharmicell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.56% |
| Shareholder Yield | -7.56% |
| Earnings Yield | -11.99% |
| FCF Yield | -2.55% |
Stock Splits
The last stock split was on December 1, 2011. It was a forward split with a ratio of 10.
| Last Split Date | Dec 1, 2011 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
Pharmicell has an Altman Z-Score of 4.6.
| Altman Z-Score | 4.6 |
| Piotroski F-Score | n/a |